Pharmaceutical M&A in the Asia Pacific Region Slowing growth continues in major developed markets, prompted by generic erosion of branded sales and increasing regulatory and cost containment pressures. Expansion into emerging Asia Pacific (APAC) markets is appealing not only because of their rapid growth and sizeable patient populations, but also because operating environments are improving as these countries open up to global trade. Overview of drivers, resistors and trends within the Asia Pacific M&A landscape.* Summary of geographic M&A activity on a regional and country-specific basis.* Analysis of the types of acquisitions and healthcare sectors targeted.* Examination of transaction values and leading dealmakers. India, Japan and Australia all continued to record frequent deal activity, although China increased its lead in terms of total deal numbers in 2010 and early 2011. However, Chinese companies continue to focus primarily on domestic transactions.Japanese companies still account for the majority of M&A deal value. The first half of 2011 has already surpassed previous peak M&A deal values in APAC, continuing the annual upward trend seen in transaction values when outlying multi-billion dollar deals are excluded.While most M&As involving APAC-based players target pharmaceutical and biological products companies, such as generics and active pharmaceutical ingredient (API) manufacturers, medical devices and equipment firms have recently taken over as the leading sector targeted for M&A. Which are the most highly valued pharmaceutical sectors for acquirers, and which companies have been the most acquisitive in APAC in recent years?* Which APAC markets have been most frequently targeted through M&As, and which have attracted the attention of Big Pharma? Strategic scoping and focusKey findingsM&A in APAC are driven by slowing growth in major markets and domestic consolidationAcquisitions are often used to gain a foothold in new Asian markets, where better healthcare is driving increased demand for quality Western medicinesChina, India, and Japan continue to dominate M&A activity in the APAC regionKey definitionsCompany classificationsAcquisition typesGeographic classificationsOtherRelated reportsUpcoming related reportsOVERVIEW OF M&A ACTIVITYKey findingsDrivers and resistors of APAC M&AStronger growth forecast in emerging compared to developed marketsChanging socio-demographics create patient demand for better healthcarePolicy and regulation changes are creating a more certain business environment in APAC marketsProduct development costs are rising rapidly in developed markets, particularly for clinical trialsOverview of M&A activity by geographyChina is the most common target location for acquisitionsChinese companies are the most common acquirersIndia is the leading APAC target for top ranking pharma companies, but China is catching upDomestic and intra-APAC deals still dominate in the regionOverview of M&A activity by deal type and size100% acquisitions are the principal deal type involving APAC companiesMinority acquisitions are not common, but are often used to solidify other types of relationshipsAcquisitions of complete business units are the most common form of asset purchaseM&A were performed by existing shareholders in a quarter of deals analyzedM&A value is likely to reach the highest annual levels in 2011The value of 100% acquisitions has been rising year-on-year in APACOverview of M&A activity by healthcare sector and therapy areaTherapeutics-focused companies are the most common APAC M&A targetsMedical technology is the most frequent target sector for M&ALeading pharma players differ slightly in their targeted sectorsAcquirers target highest value and volume therapeutic areasCOUNTRY-SPECIFIC M&A ACTIVITYKey findingsAPAC markets with significant M&A activityChinese companies continued to focus on mainly domestic M&A activityM&A activity in India is inconsistent on an annual basisJapanese companies dominated APAC M&A activity in terms of deal valueAustralian assets attracted significant international investmentAPAC markets with moderate M&A activitySingaporean companies have become more frequent targets for M&AM&A activity in South Korea increased consistently to 2010New Zealand attracted M&A partners from only a limited number of developed marketsMalaysian M&A deals are slowly increasing in frequencyThe largest proportion of M&A deals in Taiwan took place in 2008Other APAC countries were involved in few M&A dealsForeign M&A in Thailand was based on pre-existing relationshipsOnly other APAC-based companies sought deals in the PhilippinesIndonesia's single deal involved the sale of a local Big Pharma subsidiaryVietnam is still emerging as an M&A targetBIBLIOGRAPHYPublications and online articlesCompany press releasesDatamonitor productsAPPENDIXMethodologyKey definitionsCompany classificationsAcquisition typesGeographic classificationsOtherExchange rates To order this report:Pharmaceutical Industry: Pharmaceutical M&A in the Asia Pacific Region